GO:1903170 negative regulation of calcium ion transmembrane transport: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903170 describes any process that stops, prevents, or reduces the frequency, rate, or extent of calcium ion transmembrane transport.
• Calcium ion transmembrane transport is mediated by channels, pumps, and exchangers, and its negative regulation is essential for preventing calcium overload and excitotoxicity.
• Key molecular players include the calcium-sensing receptor, Klotho, TRPV6, TMEM16A, CALHM channels, and mitochondrial permeability transition regulators.
• Dysregulation of negative regulation of calcium ion transmembrane transport is implicated in aging, cancer, secretory pathway disorders, and stem cell dysfunction.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal interrogation of genes controlling this process.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study negative regulation of calcium ion transmembrane transport in disease contexts.
Description
Calcium ions (Ca2+) are universal second messengers that control processes ranging from muscle contraction and secretion to gene expression and cell death. The movement of Ca2+ across biological membranes is mediated by a diverse set of channels, pumps, and exchangers, and the frequency, rate, and extent of this transport must be tightly controlled. GO:1903170, negative regulation of calcium ion transmembrane transport, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of calcium ion transmembrane transport. This regulatory term is critical because unchecked Ca2+ influx or efflux can lead to pathological states such as excitotoxicity, mitochondrial dysfunction, and aberrant cell proliferation. Research into GO:1903170 spans multiple organ systems and disease contexts. For example, the calcium-sensing receptor and Klotho modulate Ca2+ transport in the kidney and parathyroid gland, and their dysfunction contributes to aging-related disorders. In the secretory pathway, SLC10A7 regulates O-GalNAc glycosylation and Ca2+ homeostasis, linking negative regulation of Ca2+ transport to congenital disorders of glycosylation. In cancer, CFTR-driven immune microenvironment reprogramming involves Ca2+ signaling that can be targeted with anti-PD-L1 antibodies. Understanding the molecular mechanisms that negatively regulate Ca2+ transmembrane transport is therefore essential for developing therapeutic strategies. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:1903170. We cover the definition, biological importance, core mechanisms, key genes, disease associations, and experimental models, including CRISPR-based approaches. By integrating these insights, we aim to support researchers in designing experiments that interrogate the negative regulation of calcium ion transmembrane transport.
negative regulation of calcium ion transmembrane transport At A Glance
| GO ID | GO:1903170 |
|---|---|
| GO term | negative regulation of calcium ion transmembrane transport |
| Ontology | biological_process |
| Synonym | inhibition of calcium ion transmembrane transport; downregulation of calcium ion transmembrane transport; negative regulation of transmembrane calcium transport |
| Major function | Reduces or prevents the movement of calcium ions across membranes, protecting cells from calcium overload and maintaining calcium homeostasis. |
| Related cellular components | Plasma membrane, endoplasmic reticulum, mitochondria, secretory pathway membranes |
| Related molecular functions | Calcium channel inhibitor activity, calcium pump activator activity, calcium-sensing receptor signaling |
| Associated genes | CASR, KL, TRPV6, ANO1 (TMEM16A), CALHM1, SLC10A7, CFTR, PPIF (CypD) |
| Disease relevance | Aging, cancer, congenital disorders of glycosylation, neurodegenerative disorders, stem cell dysfunction |
What Is GO:1903170?
GO:1903170, negative regulation of calcium ion transmembrane transport, is a biological process that encompasses any mechanism that stops, prevents, or reduces the frequency, rate, or extent of calcium ion transmembrane transport. This includes inhibition of calcium channels, activation of calcium pumps or exchangers that remove Ca2+ from the cytosol, and modulation of signaling pathways that control these transport proteins. The term is a negative regulatory counterpart to calcium ion transmembrane transport (GO:0070588) and is distinct from positive regulation (GO:1903169).
Why Is negative regulation of calcium ion transmembrane transport Important in Cell Biology?
Negative regulation of calcium ion transmembrane transport is fundamental to cellular physiology because calcium ions are cytotoxic when present at high concentrations for prolonged periods. This process prevents calcium overload, which can trigger mitochondrial permeability transition, apoptosis, and necrosis. It also fine-tunes calcium signaling in excitable and non-excitable cells, influencing secretion, gene expression, and immune responses. Dysregulation of this process is linked to a wide range of diseases, including cancer, neurodegeneration, and metabolic disorders. Therefore, understanding the mechanisms and genes involved in GO:1903170 is essential for both basic biology and therapeutic development.
• Prevents calcium overload and excitotoxicity in neurons and cardiac cells.
• Regulates mitochondrial permeability transition and cell death pathways.
• Modulates secretory pathway calcium homeostasis and glycosylation.
• Influences immune microenvironment reprogramming in cancer.
• Controls stem cell differentiation and development.
• Affects aging processes through Klotho and calcium-sensing receptor signaling.
• Regulates ligand-gated ion channels via neurosteroid allosteric modulation.
• Dysregulation contributes to congenital disorders of glycosylation.
• Provides targets for anti-PD-L1 antibody synergy in hepatocellular carcinoma.
• Essential for maintaining calcium homeostasis in the kidney and parathyroid gland.
What Happens During negative regulation of calcium ion transmembrane transport?
Inhibition of Calcium Influx Channels
In simple terms: Cells can block the entry of calcium through channels in the membrane.
Negative regulation of calcium ion transmembrane transport often begins with the inhibition of calcium-permeable channels. For example, TRPV6 is a highly calcium-selective channel whose activity can be downregulated by intracellular calcium, calmodulin, or phosphorylation, reducing Ca2+ influx. Similarly, TMEM16A, a calcium-activated chloride channel, can indirectly affect calcium transport by modulating membrane potential and calcium signaling. CALHM channels, which mediate ATP release and calcium homeostasis, are also subject to negative regulation. These inhibitory mechanisms prevent excessive calcium entry that could lead to cytotoxicity.
Activation of Calcium Efflux Systems
In simple terms: Cells can pump calcium out or into stores to lower its concentration in the cytoplasm.
Another key step is the activation of calcium pumps and exchangers that remove Ca2+ from the cytosol. The plasma membrane Ca2+-ATPase (PMCA) and Na+/Ca2+ exchanger (NCX) are primary efflux systems. Their activity can be enhanced by calcium-sensing receptor (CASR) signaling, which is negatively regulated by Klotho. In the secretory pathway, SLC10A7 regulates Ca2+ homeostasis, and its loss leads to altered glycosylation and Ca2+ imbalance. These efflux mechanisms are critical for restoring resting calcium levels after signaling events.
Mitochondrial Calcium Uptake and Permeability Transition
In simple terms: Mitochondria can take up calcium, but if they take up too much, they trigger cell death; negative regulation prevents this.
Mitochondria play a central role in calcium buffering. The mitochondrial calcium uniporter (MCU) mediates Ca2+ uptake, while the mitochondrial permeability transition pore (mPTP) opening is a pathological event. Negative regulation of calcium ion transmembrane transport includes mechanisms that limit mitochondrial Ca2+ overload and inhibit mPTP opening. For instance, cyclophilin D (PPIF) is a key regulator of mPTP, and its inhibition prevents calcium-induced cell death. This process is especially important in stem cells and during development.
Modulation by Neurosteroids and Allosteric Regulators
In simple terms: Certain molecules can fine-tune calcium channels by binding to them and changing their activity.
Neurosteroids act as positive and negative allosteric modulators of ligand-gated ion channels, including P2X receptors, which are permeable to calcium. By binding to these channels, neurosteroids can reduce calcium influx, thereby contributing to negative regulation of calcium ion transmembrane transport. This mechanism is particularly relevant in the nervous system, where excessive calcium entry can cause excitotoxicity.
Regulation of Calcium-Sensing Receptor Signaling
In simple terms: A sensor on the cell surface detects calcium levels and signals to reduce transport when calcium is high.
The calcium-sensing receptor (CASR) is a G protein-coupled receptor that detects extracellular Ca2+ and initiates signaling to reduce calcium transport. Klotho, an aging-suppressor protein, enhances CASR signaling and negatively regulates calcium transport in the kidney. This pathway is crucial for maintaining systemic calcium homeostasis and is implicated in aging and chronic kidney disease.
Key Genes Involved in GO:1903170 negative regulation of calcium ion transmembrane transport
The following genes and proteins are key players in the negative regulation of calcium ion transmembrane transport, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CASR | Calcium-sensing receptor; detects extracellular Ca2+ and signals to reduce transport | Aging, kidney disease, parathyroid disorders |
| KL | Klotho; enhances CASR signaling and negatively regulates Ca2+ transport | Aging, chronic kidney disease |
| TRPV6 | Calcium-selective channel; its inhibition reduces Ca2+ influx | Cancer, calcium homeostasis |
| ANO1 (TMEM16A) | Calcium-activated chloride channel; modulates calcium signaling | Cancer, cystic fibrosis, hypertension |
| CALHM1 | Calcium homeostasis modulator; regulates ATP release and Ca2+ transport | Alzheimer's disease, taste perception |
| SLC10A7 | Regulates O-GalNAc glycosylation and Ca2+ homeostasis in secretory pathway | Congenital disorders of glycosylation |
| CFTR | Chloride channel; influences immune microenvironment and Ca2+ signaling | Hepatocellular carcinoma, cystic fibrosis |
| PPIF (CypD) | Cyclophilin D; regulates mitochondrial permeability transition pore | Stem cell death, neurodegeneration |
| P2RX | ATP-gated ion channel; permeable to Ca2+, modulated by neurosteroids | Neuropathic pain, inflammation |
| MCU | Mitochondrial calcium uniporter; mediates Ca2+ uptake | Mitochondrial dysfunction, ischemia |
| ATP2B1 (PMCA1) | Plasma membrane Ca2+-ATPase; pumps Ca2+ out of cell | Hypertension, calcium homeostasis |
| SLC8A1 (NCX1) | Na+/Ca2+ exchanger; removes Ca2+ from cytosol | Cardiac arrhythmia, heart failure |
| CALM1 | Calmodulin; regulates calcium channels and pumps | Long QT syndrome, calcium signaling |
| CACNA1C | Voltage-gated calcium channel; can be negatively regulated | Timothy syndrome, psychiatric disorders |
| GRIN1 | NMDA receptor subunit; calcium-permeable, subject to negative regulation | Neurodegeneration, schizophrenia |
| GABRA1 | GABA-A receptor subunit; modulates calcium influx indirectly | Epilepsy, anxiety |
| HTR3A | Serotonin receptor; calcium-permeable, modulated by neurosteroids | Nausea, irritable bowel syndrome |
| CHRNA7 | Nicotinic acetylcholine receptor; calcium-permeable | Alzheimer's disease, schizophrenia |
How Is negative regulation of calcium ion transmembrane transport Regulated?
The negative regulation of calcium ion transmembrane transport is itself controlled by multiple signaling pathways. The calcium-sensing receptor (CASR) and Klotho form a key axis that responds to extracellular calcium levels and downregulates transport. In the secretory pathway, SLC10A7 regulates Ca2+ homeostasis, and its dysfunction leads to glycosylation defects. Mitochondrial calcium handling is regulated by the mitochondrial permeability transition pore, with cyclophilin D (PPIF) as a critical modulator. Neurosteroids can allosterically inhibit calcium-permeable ligand-gated ion channels, providing an additional layer of regulation. These pathways ensure that calcium transport is finely tuned to cellular needs.
negative regulation of calcium ion transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFTR | Hepatocellular carcinoma, immune microenvironment | CFTR knockout in HepG2 cells; anti-PD-L1 treatment |
| SLC10A7 | Congenital disorder of glycosylation (SLC10A7-CDG) | SLC10A7 knockout HEK293 cells; glycosylation and Ca2+ imaging |
| KL | Aging, chronic kidney disease | Klotho knockout mouse; calcium transport assays |
| TRPV6 | Cancer, calcium homeostasis | TRPV6 overexpression in prostate cancer cells; patch clamp |
| PPIF | Mitochondrial permeability transition, neurodegeneration | PPIF knockout MEFs; calcium retention capacity |
Cancer and Immune Microenvironment
Dysregulation of calcium transport is increasingly recognized in cancer. CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma, suggesting that calcium signaling pathways can be targeted to enhance immunotherapy. TRPV6, a calcium-selective channel, is overexpressed in several cancers, and its negative regulation may suppress tumor growth. TMEM16A is also implicated in cancer progression and is a potential therapeutic target.
Aging and Metabolic Disorders
Klotho and CASR are central to aging and metabolic regulation. Klotho deficiency leads to accelerated aging and disrupted calcium homeostasis. Negative regulation of calcium transport by Klotho-CASR signaling is protective against chronic kidney disease and vascular calcification. Targeting this pathway may offer therapeutic benefits for age-related disorders.
Congenital Disorders of Glycosylation
SLC10A7 mutations cause a congenital disorder of glycosylation (SLC10A7-CDG) characterized by skeletal and dental anomalies. SLC10A7 regulates O-GalNAc glycosylation and Ca2+ homeostasis in the secretory pathway, linking negative regulation of calcium transport to glycosylation defects. This highlights the importance of calcium regulation in secretory pathway function.
Neurodegeneration and Excitotoxicity
Excessive calcium influx through NMDA receptors and other calcium-permeable channels leads to excitotoxicity, a hallmark of neurodegenerative diseases. Negative regulation of calcium ion transmembrane transport, including modulation by neurosteroids of P2X receptors, protects neurons from calcium overload. Mitochondrial permeability transition, regulated by cyclophilin D, is also implicated in neuronal death.
From negative regulation of calcium ion transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CASR increase calcium transport? | CASR knockout HEK293 cells; calcium imaging |
| How does SLC10A7 mutation affect Ca2+ homeostasis? | SLC10A7 point mutation knock-in HEK293 cells; live-cell Ca2+ imaging |
| Can TRPV6 inhibition reduce cancer cell proliferation? | TRPV6 knockout or point mutation in prostate cancer cell lines |
| What is the role of TMEM16A in calcium signaling? | TMEM16A knockout or overexpression in airway epithelial cells |
| Does CFTR modulation affect anti-PD-L1 response? | CFTR knockout in hepatocellular carcinoma cells; co-culture with T cells |
| How does cyclophilin D regulate mPTP? | PPIF knockout or point mutation in stem cells; calcium-induced swelling |
How to Study the negative regulation of calcium ion transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell Ca2+ imaging | Intracellular calcium concentration dynamics | Assessing negative regulation by CASR/Klotho |
| Patch-clamp electrophysiology | Ion channel activity and inhibition | TRPV6 and TMEM16A regulation |
| CRISPR knockout screens | Gene essentiality and regulatory pathways | Identifying novel negative regulators |
| Proximity labeling (BioID) | Protein-protein interactions | Mapping calcium channel complexes |
| Mitochondrial swelling assay | Permeability transition pore opening | PPIF function in stem cells |
| Glycosylation analysis | O-GalNAc glycosylation status | SLC10A7-CDG modeling |
| Immune cell co-culture | T cell activation and killing | CFTR and anti-PD-L1 synergy |
| Neurosteroid modulation assays | Allosteric effects on ligand-gated channels | P2X receptor regulation |
Calcium Imaging and Flux Assays
Live-cell calcium imaging using fluorescent dyes (e.g., Fura-2, Fluo-4) or genetically encoded indicators (GCaMP) allows real-time measurement of calcium transport across membranes. These methods are essential to quantify the effects of negative regulators. Patch-clamp electrophysiology can directly measure calcium channel activity and its inhibition.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate calcium ion transmembrane transport. For example, a screen for regulators of calcium homeostasis in the secretory pathway could uncover SLC10A7 and related genes. These screens are powerful for discovering novel regulators and drug targets.
Proteomics and Interactomics
Affinity purification mass spectrometry (AP-MS) and proximity labeling (BioID) can identify protein complexes involved in calcium transport regulation. For instance, interacting partners of TRPV6 or TMEM16A can be mapped to understand negative regulation. Phosphoproteomics can reveal signaling events that inhibit calcium channels.
Mitochondrial Function Assays
Mitochondrial calcium retention capacity and permeability transition pore opening can be measured using isolated mitochondria or permeabilized cells. These assays are critical for studying the role of cyclophilin D (PPIF) and other regulators of mitochondrial calcium transport.
How CRISPR Can Be Used to Study GO:1903170 negative regulation of calcium ion transmembrane transport
Knockout
CRISPR knockout of genes such as CASR, KL, TRPV6, or SLC10A7 can abolish their negative regulatory function, leading to increased calcium transport. These models are invaluable for studying loss-of-function phenotypes in calcium overload diseases. For example, SLC10A7 knockout cells exhibit altered Ca2+ homeostasis and glycosylation defects.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific regulatory domains. For instance, introducing a point mutation in TRPV6 that prevents calmodulin binding can test its role in negative regulation. Similarly, point mutations in CFTR can affect its interaction with calcium signaling pathways.
Knock-in
Knock-in of tagged versions of calcium channels or pumps (e.g., GFP-TRPV6) allows real-time tracking and interaction studies. Knock-in of disease-relevant mutations, such as those in SLC10A7, can model congenital disorders of glycosylation. These models are essential for understanding precise molecular mechanisms.
Overexpression
Overexpression of negative regulators such as Klotho or CASR can enhance calcium transport inhibition and protect against calcium overload. Overexpression models are useful for gain-of-function studies and for testing therapeutic candidates. For example, Klotho overexpression extends lifespan and improves calcium homeostasis in mice.
How EDITGENE Supports negative regulation of calcium ion transmembrane transport Research
Researchers studying negative regulation of calcium ion transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. CRISPR-based cell models provide the gold standard for establishing causality, enabling precise genetic perturbations that reveal gene function in calcium homeostasis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of calcium ion transmembrane transport research.
Frequently Asked Questions About negative regulation of calcium ion transmembrane transport
What is GO:1903170?
GO:1903170 is a Gene Ontology biological process term that describes any process that stops, prevents, or reduces the frequency, rate, or extent of calcium ion transmembrane transport.
What genes are involved in negative regulation of calcium ion transmembrane transport?
Key genes include CASR, KL (Klotho), TRPV6, ANO1 (TMEM16A), CALHM1, SLC10A7, CFTR, and PPIF (cyclophilin D).
How does calcium ion transmembrane transport get negatively regulated?
It is regulated by inhibition of calcium channels, activation of calcium pumps/exchangers, mitochondrial calcium buffering, and allosteric modulation by neurosteroids.
Why is negative regulation of calcium transport important?
It prevents calcium overload and excitotoxicity, maintains calcium homeostasis, and protects against diseases such as cancer, neurodegeneration, and metabolic disorders.
What diseases are associated with defective negative regulation of calcium transport?
Diseases include hepatocellular carcinoma, congenital disorders of glycosylation, chronic kidney disease, neurodegeneration, and aging-related disorders.
How can I study negative regulation of calcium ion transmembrane transport?
Use live-cell calcium imaging, patch-clamp electrophysiology, CRISPR screens, proteomics, and mitochondrial function assays.
What CRISPR models are available for calcium transport research?
Knockout, point mutation, knock-in, and overexpression models can be generated for genes like CASR, TRPV6, SLC10A7, and CFTR.
What is the role of Klotho in calcium transport?
Klotho enhances calcium-sensing receptor signaling and negatively regulates calcium transport, playing a key role in aging and kidney disease.
How does SLC10A7 relate to calcium homeostasis?
SLC10A7 regulates O-GalNAc glycosylation and Ca2+ homeostasis in the secretory pathway; its mutations cause SLC10A7-CDG.
Can CFTR modulation affect cancer immunotherapy?
Yes, CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma, involving calcium signaling.
Conclusion
GO:1903170, negative regulation of calcium ion transmembrane transport, is a critical biological process that safeguards cells against calcium overload and maintains calcium homeostasis. Its dysregulation is implicated in a broad spectrum of diseases, from cancer and neurodegeneration to congenital disorders of glycosylation and aging. Understanding the molecular players and mechanisms, such as CASR, Klotho, TRPV6, SLC10A7, and mitochondrial regulators, provides opportunities for therapeutic intervention. CRISPR-based cell models and screening approaches are indispensable tools for dissecting this process and identifying new drug targets. EDITGENE offers comprehensive services to support these research endeavors, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Kuro-o M. 2009. Klotho and aging.. Biochim Biophys Acta 1790(10):1049-58 PMID: 19230844
- 2. Xu Y et al.. 2026. CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma.. Cell Death Dis 17(1) PMID: 42270598
- 3. Durin Z et al.. 2025. SLC10A7 regulates O-GalNAc glycosylation and Ca(2+) homeostasis in the secretory pathway: insights into SLC10A7-CDG.. Cell Mol Life Sci 82(1):40 PMID: 39779512
- 4. Yelshanskaya MV et al.. 2021. Structure and function of the calcium-selective TRP channel TRPV6.. J Physiol 599(10):2673-2697 PMID: 32073143
- 5. Arreola J et al.. 2024. Insights into the function and regulation of the calcium-activated chloride channel TMEM16A.. Cell Calcium 121:102891 PMID: 38772195
- 6. Ma Z et al.. 2016. Calcium homeostasis modulator (CALHM) ion channels.. Pflugers Arch 468(3):395-403 PMID: 26603282
- 7. Sivcev S et al.. 2023. Neurosteroids as positive and negative allosteric modulators of ligand-gated ion channels: P2X receptor perspective.. Neuropharmacology 234:109542 PMID: 37040816
- 8. Dumbali SP et al.. 2023. Mitochondrial Permeability Transition in Stem Cells, Development, and Disease.. Adv Exp Med Biol 1409:1-22 PMID: 35739412
